Portal de Periódicos da CAPES

Effect of Atorvastatin on Hematologic Parameters in Patients With Hypercholesterolemia

2013; SAGE Publishing; Volume: 64; Issue: 8 Linguagem: Inglês

10.1177/0003319713479154

1940-1574

Fatih Akın, Burak Ayça, Nuri Köse, İrfan Şahin, Melike Nur Akın, Tuğba Dübektaş Canbek, Ömer Güngör,

Lipid metabolism and disorders

Hematologic parameters such as mean platelet volume (MPV), red cell distribution width (RDW), and neutrophil to lymphocyte (N/L) ratio are associated with increased cardiovascular risk. We investigated the effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia. A total of 79 patients with hypercholesterolemia and 47 normocholesterolemic healthy participants were included. Patients with hypercholesterolemia received 10 to 80 mg/d atorvastatin during a 24-week period. Hematologic parameters were measured at baseline and after 6 months. Atorvastatin treatment produced a significant decrease in MPV levels (9.3 ± 1.3 vs 9.1 ± 1.2 fL, P = .008) and platelet count (259 ± 61 vs 248 ± 51 10 9 /L, P = .005). The N/L ratio decreased significantly after atorvastatin treatment from 2.9 ± 1.2 to 2.6 ± 1.1, ( P = .014). The RDW and platelet distribution width levels were not different among the study groups, before and after treatment. Atorvastatin may beneficially reduce MPV levels and N/L ratio. This antiplatelet and anti-inflammatory effect of atorvastatin treatment could play a role in reducing cardiovascular risk.